Argos Therapeutics Inc. (NASDAQ:ARGS) shares traded up 6.6% on Friday . The stock traded as high as $6.24 and last traded at $6.13, with a volume of 120,453 shares trading hands. The stock had previously closed at $5.75.

Several research analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, March 19th. Zacks Investment Research cut Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research note on Monday, June 20th. Finally, Roth Capital raised their target price on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 19th. Eight analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $11.84.

The stock has a 50 day moving average of $6.10 and a 200 day moving average of $5.26. The firm’s market capitalization is $161.56 million.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.01. On average, analysts predict that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.